[RUN_AMAF] provider=lambda | model=deepseek-r1-0528
DEBUG: Initializing agent TabuSynth with provider=lambda, model=deepseek-r1-0528
DEBUG: Initializing agent Contextron with provider=lambda, model=deepseek-r1-0528
DEBUG: Initializing agent Visura with provider=lambda, model=deepseek-r1-0528
DEBUG: Initializing agent SummaCraft with provider=lambda, model=deepseek-r1-0528
DEBUG: Initializing agent TrendAnalyser with provider=lambda, model=deepseek-r1-0528
DEBUG: Initializing agent MCP with provider=lambda, model=deepseek-r1-0528
DEBUG: _chat called with provider=lambda, model=deepseek-r1-0528
DEBUG: Using OpenAI client.chat.completions.create() with model=deepseek-r1-0528
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>
DEBUG: _chat called with provider=lambda, model=deepseek-r1-0528
DEBUG: Using OpenAI client.chat.completions.create() with model=deepseek-r1-0528
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>
DEBUG: _chat called with provider=lambda, model=deepseek-r1-0528
DEBUG: Using OpenAI client.chat.completions.create() with model=deepseek-r1-0528
DEBUG: OpenAI API call successful, response type: <class 'openai.types.chat.chat_completion.ChatCompletion'>

=== FINAL SUMMARY ===

{
  "71724d7e-77ae-4c4c-be12-73ca0443372d": [
    "The increase was primarily driven by grants from the European Commission IPCEI programs in Italy and France (part of Research and development funding), partially offset by higher start-up costs in Singapore.",
    ""
  ],
  "75623d36-47ae-4801-9727-ee17b04cd8e5": [
    "The decrease was primarily due to lower R&D grants (part of Research and development funding), which dropped to $52M (2018) from $65M (2017).",
    ""
  ],
  "bc38890b-c504-46e2-9546-765af952bdc5": [
    "55",
    "million"
  ],
  "a3ea64bc-4447-4c0b-b76c-84575a3a0de2": [
    "83",
    "million"
  ],
  "33de3029-3056-4598-bdff-30d9be4f52c3": [
    "6.3",
    "million"
  ],
  "cd3367c7-d3bd-440c-8c51-90a6ee95cc77": [
    "67",
    "million"
  ]
}

=== LOGS (per-agent) ===
{'TabuSynth': {'cot': '### Answers for Table: '
                      '2cf767c9-a0f8-4d78-b6f2-71221f566c2f\n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 71724d7e-77ae-4c4c-be12-73ca0443372d**  \n'
                      '**Question:** What led to increase in other income, net '
                      'of expenses in 2019?  \n'
                      '**Answer:** The increase was primarily driven by a '
                      'significant rise in Research and development funding '
                      '($132M in 2019 vs. $52M in 2018).  \n'
                      '**Evidence:**  \n'
                      '- Research and development funding increased from $52M '
                      '(2018, row 3, column 3) to $132M (2019, row 3, column '
                      '2).  \n'
                      '- Partially offset by higher Phase-out and start-up '
                      'costs: -$38M (2019, row 4, column 2) vs. -$1M (2018, '
                      'row 4, column 3).  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 2-3 (Research and development '
                      'funding)  \n'
                      '- Row 4, columns 2-3 (Phase-out and start-up costs)  \n'
                      '**Missing Information:** None.  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 75623d36-47ae-4801-9727-ee17b04cd8e5**  \n'
                      '**Question:** What led to decrease in other income, net '
                      'of expenses in 2018?  \n'
                      '**Answer:** The decrease was primarily due to a drop in '
                      'Research and development funding ($52M in 2018 vs. $65M '
                      'in 2017).  \n'
                      '**Evidence:**  \n'
                      '- Research and development funding decreased from $65M '
                      '(2017, row 3, column 4) to $52M (2018, row 3, column '
                      '3).  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 3-4 (Research and development '
                      'funding)  \n'
                      '**Missing Information:** None.  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: bc38890b-c504-46e2-9546-765af952bdc5**  \n'
                      '**Question:** What was the other income, net of '
                      'expenses in 2017?  \n'
                      '**Answer:** $55 million  \n'
                      '**Evidence:**  \n'
                      '- "Other income and expenses, net" value for 2017: $55 '
                      '(row 9, column 4).  \n'
                      '**Table Data Used:**  \n'
                      '- Row 9, column 4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: a3ea64bc-4447-4c0b-b76c-84575a3a0de2**  \n'
                      '**Question:** What is the average Research and '
                      'development funding?  \n'
                      '**Answer:** 83 million dollars  \n'
                      '**Evidence:**  \n'
                      '- Values: $65M (2017, row 3, column 4), $52M (2018, row '
                      '3, column 3), $132M (2019, row 3, column 2).  \n'
                      '- Calculation: ($65 + $52 + $132) / 3 = $249 / 3 = '
                      '$83M.  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 2-4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 33de3029-3056-4598-bdff-30d9be4f52c3**  \n'
                      '**Question:** What is the average gain on sale of '
                      'businesses and non-current assets?  \n'
                      '**Answer:** 6.3 million dollars  \n'
                      '**Evidence:**  \n'
                      '- Values: $7M (2019, row 7, column 2), $8M (2018, row '
                      '7, column 3), $4M (2017, row 7, column 4).  \n'
                      '- Calculation: ($7 + $8 + $4) / 3 = $19 / 3 ≈ $6.3M.  \n'
                      '**Table Data Used:**  \n'
                      '- Row 7, columns 2-4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: cd3367c7-d3bd-440c-8c51-90a6ee95cc77**  \n'
                      '**Question:** What is the increase/ (decrease) in '
                      'Research and development funding from 2017 to 2019?  \n'
                      '**Answer:** 67 million dollars (increase)  \n'
                      '**Evidence:**  \n'
                      '- 2017: $65M (row 3, column 4).  \n'
                      '- 2019: $132M (row 3, column 2).  \n'
                      '- Change: $132M - $65M = $67M increase.  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 2 and 4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '--- \n'
                      '\n'
                      '**Summary of Table References Used:**  \n'
                      '- Research and development funding: Row 3  \n'
                      '- Phase-out and start-up costs: Row 4  \n'
                      '- Other income and expenses, net: Row 9  \n'
                      '- Gain on sale of businesses and non-current assets: '
                      'Row 7  \n'
                      '- Columns: 2 (2019), 3 (2018), 4 (2017)',
               'result': '### Answers for Table: '
                         '2cf767c9-a0f8-4d78-b6f2-71221f566c2f\n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: 71724d7e-77ae-4c4c-be12-73ca0443372d**  \n'
                         '**Question:** What led to increase in other income, '
                         'net of expenses in 2019?  \n'
                         '**Answer:** The increase was primarily driven by a '
                         'significant rise in Research and development funding '
                         '($132M in 2019 vs. $52M in 2018).  \n'
                         '**Evidence:**  \n'
                         '- Research and development funding increased from '
                         '$52M (2018, row 3, column 3) to $132M (2019, row 3, '
                         'column 2).  \n'
                         '- Partially offset by higher Phase-out and start-up '
                         'costs: -$38M (2019, row 4, column 2) vs. -$1M (2018, '
                         'row 4, column 3).  \n'
                         '**Table Data Used:**  \n'
                         '- Row 3, columns 2-3 (Research and development '
                         'funding)  \n'
                         '- Row 4, columns 2-3 (Phase-out and start-up '
                         'costs)  \n'
                         '**Missing Information:** None.  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: 75623d36-47ae-4801-9727-ee17b04cd8e5**  \n'
                         '**Question:** What led to decrease in other income, '
                         'net of expenses in 2018?  \n'
                         '**Answer:** The decrease was primarily due to a drop '
                         'in Research and development funding ($52M in 2018 '
                         'vs. $65M in 2017).  \n'
                         '**Evidence:**  \n'
                         '- Research and development funding decreased from '
                         '$65M (2017, row 3, column 4) to $52M (2018, row 3, '
                         'column 3).  \n'
                         '**Table Data Used:**  \n'
                         '- Row 3, columns 3-4 (Research and development '
                         'funding)  \n'
                         '**Missing Information:** None.  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: bc38890b-c504-46e2-9546-765af952bdc5**  \n'
                         '**Question:** What was the other income, net of '
                         'expenses in 2017?  \n'
                         '**Answer:** $55 million  \n'
                         '**Evidence:**  \n'
                         '- "Other income and expenses, net" value for 2017: '
                         '$55 (row 9, column 4).  \n'
                         '**Table Data Used:**  \n'
                         '- Row 9, column 4  \n'
                         '**Scale:** million  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: a3ea64bc-4447-4c0b-b76c-84575a3a0de2**  \n'
                         '**Question:** What is the average Research and '
                         'development funding?  \n'
                         '**Answer:** 83 million dollars  \n'
                         '**Evidence:**  \n'
                         '- Values: $65M (2017, row 3, column 4), $52M (2018, '
                         'row 3, column 3), $132M (2019, row 3, column 2).  \n'
                         '- Calculation: ($65 + $52 + $132) / 3 = $249 / 3 = '
                         '$83M.  \n'
                         '**Table Data Used:**  \n'
                         '- Row 3, columns 2-4  \n'
                         '**Scale:** million  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: 33de3029-3056-4598-bdff-30d9be4f52c3**  \n'
                         '**Question:** What is the average gain on sale of '
                         'businesses and non-current assets?  \n'
                         '**Answer:** 6.3 million dollars  \n'
                         '**Evidence:**  \n'
                         '- Values: $7M (2019, row 7, column 2), $8M (2018, '
                         'row 7, column 3), $4M (2017, row 7, column 4).  \n'
                         '- Calculation: ($7 + $8 + $4) / 3 = $19 / 3 ≈ '
                         '$6.3M.  \n'
                         '**Table Data Used:**  \n'
                         '- Row 7, columns 2-4  \n'
                         '**Scale:** million  \n'
                         '\n'
                         '---\n'
                         '\n'
                         '**QID: cd3367c7-d3bd-440c-8c51-90a6ee95cc77**  \n'
                         '**Question:** What is the increase/ (decrease) in '
                         'Research and development funding from 2017 to '
                         '2019?  \n'
                         '**Answer:** 67 million dollars (increase)  \n'
                         '**Evidence:**  \n'
                         '- 2017: $65M (row 3, column 4).  \n'
                         '- 2019: $132M (row 3, column 2).  \n'
                         '- Change: $132M - $65M = $67M increase.  \n'
                         '**Table Data Used:**  \n'
                         '- Row 3, columns 2 and 4  \n'
                         '**Scale:** million  \n'
                         '\n'
                         '--- \n'
                         '\n'
                         '**Summary of Table References Used:**  \n'
                         '- Research and development funding: Row 3  \n'
                         '- Phase-out and start-up costs: Row 4  \n'
                         '- Other income and expenses, net: Row 9  \n'
                         '- Gain on sale of businesses and non-current assets: '
                         'Row 7  \n'
                         '- Columns: 2 (2019), 3 (2018), 4 (2017)',
               'raw': '### Answers for Table: '
                      '2cf767c9-a0f8-4d78-b6f2-71221f566c2f\n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 71724d7e-77ae-4c4c-be12-73ca0443372d**  \n'
                      '**Question:** What led to increase in other income, net '
                      'of expenses in 2019?  \n'
                      '**Answer:** The increase was primarily driven by a '
                      'significant rise in Research and development funding '
                      '($132M in 2019 vs. $52M in 2018).  \n'
                      '**Evidence:**  \n'
                      '- Research and development funding increased from $52M '
                      '(2018, row 3, column 3) to $132M (2019, row 3, column '
                      '2).  \n'
                      '- Partially offset by higher Phase-out and start-up '
                      'costs: -$38M (2019, row 4, column 2) vs. -$1M (2018, '
                      'row 4, column 3).  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 2-3 (Research and development '
                      'funding)  \n'
                      '- Row 4, columns 2-3 (Phase-out and start-up costs)  \n'
                      '**Missing Information:** None.  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 75623d36-47ae-4801-9727-ee17b04cd8e5**  \n'
                      '**Question:** What led to decrease in other income, net '
                      'of expenses in 2018?  \n'
                      '**Answer:** The decrease was primarily due to a drop in '
                      'Research and development funding ($52M in 2018 vs. $65M '
                      'in 2017).  \n'
                      '**Evidence:**  \n'
                      '- Research and development funding decreased from $65M '
                      '(2017, row 3, column 4) to $52M (2018, row 3, column '
                      '3).  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 3-4 (Research and development '
                      'funding)  \n'
                      '**Missing Information:** None.  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: bc38890b-c504-46e2-9546-765af952bdc5**  \n'
                      '**Question:** What was the other income, net of '
                      'expenses in 2017?  \n'
                      '**Answer:** $55 million  \n'
                      '**Evidence:**  \n'
                      '- "Other income and expenses, net" value for 2017: $55 '
                      '(row 9, column 4).  \n'
                      '**Table Data Used:**  \n'
                      '- Row 9, column 4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: a3ea64bc-4447-4c0b-b76c-84575a3a0de2**  \n'
                      '**Question:** What is the average Research and '
                      'development funding?  \n'
                      '**Answer:** 83 million dollars  \n'
                      '**Evidence:**  \n'
                      '- Values: $65M (2017, row 3, column 4), $52M (2018, row '
                      '3, column 3), $132M (2019, row 3, column 2).  \n'
                      '- Calculation: ($65 + $52 + $132) / 3 = $249 / 3 = '
                      '$83M.  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 2-4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: 33de3029-3056-4598-bdff-30d9be4f52c3**  \n'
                      '**Question:** What is the average gain on sale of '
                      'businesses and non-current assets?  \n'
                      '**Answer:** 6.3 million dollars  \n'
                      '**Evidence:**  \n'
                      '- Values: $7M (2019, row 7, column 2), $8M (2018, row '
                      '7, column 3), $4M (2017, row 7, column 4).  \n'
                      '- Calculation: ($7 + $8 + $4) / 3 = $19 / 3 ≈ $6.3M.  \n'
                      '**Table Data Used:**  \n'
                      '- Row 7, columns 2-4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '---\n'
                      '\n'
                      '**QID: cd3367c7-d3bd-440c-8c51-90a6ee95cc77**  \n'
                      '**Question:** What is the increase/ (decrease) in '
                      'Research and development funding from 2017 to 2019?  \n'
                      '**Answer:** 67 million dollars (increase)  \n'
                      '**Evidence:**  \n'
                      '- 2017: $65M (row 3, column 4).  \n'
                      '- 2019: $132M (row 3, column 2).  \n'
                      '- Change: $132M - $65M = $67M increase.  \n'
                      '**Table Data Used:**  \n'
                      '- Row 3, columns 2 and 4  \n'
                      '**Scale:** million  \n'
                      '\n'
                      '--- \n'
                      '\n'
                      '**Summary of Table References Used:**  \n'
                      '- Research and development funding: Row 3  \n'
                      '- Phase-out and start-up costs: Row 4  \n'
                      '- Other income and expenses, net: Row 9  \n'
                      '- Gain on sale of businesses and non-current assets: '
                      'Row 7  \n'
                      '- Columns: 2 (2019), 3 (2018), 4 (2017)'},
 'Contextron': {'cot': '**Question 1**: What led to increase in other income, '
                       'net of expenses in 2019?  \n'
                       '**Answer**: The increase was primarily driven by '
                       'grants from the European Commission IPCEI programs in '
                       'Italy and France (part of Research and development '
                       'funding), partially offset by higher start-up costs in '
                       'Singapore. Specifically:  \n'
                       '- Research and development funding increased to $132M '
                       '(2019) from $52M (2018)  \n'
                       '- Phase-out and start-up costs rose to -$38M (2019) '
                       'from -$1M (2018)  \n'
                       '**Source**: table-text  \n'
                       '**Type**: text',
                'result': '**Question 2**: What led to decrease in other '
                          'income, net of expenses in 2018?  \n'
                          '**Answer**: The decrease was primarily due to lower '
                          'R&D grants (part of Research and development '
                          'funding), which dropped to $52M (2018) from $65M '
                          '(2017).  \n'
                          '**Source**: table-text  \n'
                          '**Type**: text  \n'
                          '\n'
                          '**Question 3**: What was the other income, net of '
                          'expenses in 2017?  \n'
                          '**Answer**: $55 million  \n'
                          '**Source**: table (confirmed by text)  \n'
                          '**Type**: span  \n'
                          '\n'
                          '**Question 4**: What is the average Research and '
                          'development funding?  \n'
                          '**Answer**: 83 million dollars  \n'
                          '**Source**: table  \n'
                          '**Type**: arithmetic  \n'
                          '\n'
                          '**Question 5**: What is the average gain on sale of '
                          'businesses and non-current assets?  \n'
                          '**Answer**: 6.3 million dollars  \n'
                          '**Source**: table  \n'
                          '**Type**: arithmetic  \n'
                          '\n'
                          '**Question 6**: What is the increase/ (decrease) in '
                          'Research and development funding from 2017 to '
                          '2019?  \n'
                          '**Answer**: 67 million dollars (increase)  \n'
                          '**Source**: table  \n'
                          '**Type**: arithmetic  \n'
                          '\n'
                          '---\n'
                          '\n'
                          '### Textual Context Summary for Downstream '
                          'Agents:  \n'
                          'In 2019, other income (net of expenses) rose to '
                          '$103M from $53M in 2018, driven by European '
                          'Commission IPCEI grants in Italy/France but '
                          'partially offset by Singapore start-up costs. In '
                          '2018, other income decreased to $53M from $55M in '
                          '2017 due to lower R&D grants. All values in '
                          'millions of dollars.',
                'raw': '**Question 1**: What led to increase in other income, '
                       'net of expenses in 2019?  \n'
                       '**Answer**: The increase was primarily driven by '
                       'grants from the European Commission IPCEI programs in '
                       'Italy and France (part of Research and development '
                       'funding), partially offset by higher start-up costs in '
                       'Singapore. Specifically:  \n'
                       '- Research and development funding increased to $132M '
                       '(2019) from $52M (2018)  \n'
                       '- Phase-out and start-up costs rose to -$38M (2019) '
                       'from -$1M (2018)  \n'
                       '**Source**: table-text  \n'
                       '**Type**: text  \n'
                       '\n'
                       '**Question 2**: What led to decrease in other income, '
                       'net of expenses in 2018?  \n'
                       '**Answer**: The decrease was primarily due to lower '
                       'R&D grants (part of Research and development funding), '
                       'which dropped to $52M (2018) from $65M (2017).  \n'
                       '**Source**: table-text  \n'
                       '**Type**: text  \n'
                       '\n'
                       '**Question 3**: What was the other income, net of '
                       'expenses in 2017?  \n'
                       '**Answer**: $55 million  \n'
                       '**Source**: table (confirmed by text)  \n'
                       '**Type**: span  \n'
                       '\n'
                       '**Question 4**: What is the average Research and '
                       'development funding?  \n'
                       '**Answer**: 83 million dollars  \n'
                       '**Source**: table  \n'
                       '**Type**: arithmetic  \n'
                       '\n'
                       '**Question 5**: What is the average gain on sale of '
                       'businesses and non-current assets?  \n'
                       '**Answer**: 6.3 million dollars  \n'
                       '**Source**: table  \n'
                       '**Type**: arithmetic  \n'
                       '\n'
                       '**Question 6**: What is the increase/ (decrease) in '
                       'Research and development funding from 2017 to 2019?  \n'
                       '**Answer**: 67 million dollars (increase)  \n'
                       '**Source**: table  \n'
                       '**Type**: arithmetic  \n'
                       '\n'
                       '---\n'
                       '\n'
                       '### Textual Context Summary for Downstream Agents:  \n'
                       'In 2019, other income (net of expenses) rose to $103M '
                       'from $53M in 2018, driven by European Commission IPCEI '
                       'grants in Italy/France but partially offset by '
                       'Singapore start-up costs. In 2018, other income '
                       'decreased to $53M from $55M in 2017 due to lower R&D '
                       'grants. All values in millions of dollars.'},
 'SummaCraft': {'cot': '(omitted)',
                'result': '{\n'
                          '  "71724d7e-77ae-4c4c-be12-73ca0443372d": [\n'
                          '    "The increase was primarily driven by grants '
                          'from the European Commission IPCEI programs in '
                          'Italy and France (part of Research and development '
                          'funding), partially offset by higher start-up costs '
                          'in Singapore.",\n'
                          '    ""\n'
                          '  ],\n'
                          '  "75623d36-47ae-4801-9727-ee17b04cd8e5": [\n'
                          '    "The decrease was primarily due to lower R&D '
                          'grants (part of Research and development funding), '
                          'which dropped to $52M (2018) from $65M (2017).",\n'
                          '    ""\n'
                          '  ],\n'
                          '  "bc38890b-c504-46e2-9546-765af952bdc5": [\n'
                          '    "55",\n'
                          '    "million"\n'
                          '  ],\n'
                          '  "a3ea64bc-4447-4c0b-b76c-84575a3a0de2": [\n'
                          '    "83",\n'
                          '    "million"\n'
                          '  ],\n'
                          '  "33de3029-3056-4598-bdff-30d9be4f52c3": [\n'
                          '    "6.3",\n'
                          '    "million"\n'
                          '  ],\n'
                          '  "cd3367c7-d3bd-440c-8c51-90a6ee95cc77": [\n'
                          '    "67",\n'
                          '    "million"\n'
                          '  ]\n'
                          '}',
                'raw': '### Final Answer Synthesis\n'
                       '\n'
                       'Based on the inputs from TabuSynth and Contextron '
                       "agents, I've synthesized the answers following TATQA "
                       "submission guidelines. Contextron's answers are "
                       'prioritized where available since they incorporate '
                       'both table and text evidence.\n'
                       '\n'
                       '```json\n'
                       '{\n'
                       '  "71724d7e-77ae-4c4c-be12-73ca0443372d": [\n'
                       '    "The increase was primarily driven by grants from '
                       'the European Commission IPCEI programs in Italy and '
                       'France (part of Research and development funding), '
                       'partially offset by higher start-up costs in '
                       'Singapore.", \n'
                       '    ""\n'
                       '  ],\n'
                       '  "75623d36-47ae-4801-9727-ee17b04cd8e5": [\n'
                       '    "The decrease was primarily due to lower R&D '
                       'grants (part of Research and development funding), '
                       'which dropped to $52M (2018) from $65M (2017).", \n'
                       '    ""\n'
                       '  ],\n'
                       '  "bc38890b-c504-46e2-9546-765af952bdc5": [\n'
                       '    "55", \n'
                       '    "million"\n'
                       '  ],\n'
                       '  "a3ea64bc-4447-4c0b-b76c-84575a3a0de2": [\n'
                       '    "83", \n'
                       '    "million"\n'
                       '  ],\n'
                       '  "33de3029-3056-4598-bdff-30d9be4f52c3": [\n'
                       '    "6.3", \n'
                       '    "million"\n'
                       '  ],\n'
                       '  "cd3367c7-d3bd-440c-8c51-90a6ee95cc77": [\n'
                       '    "67", \n'
                       '    "million"\n'
                       '  ]\n'
                       '}\n'
                       '```\n'
                       '\n'
                       '### Synthesis Rationale:\n'
                       '1. **Explanatory questions (Q1-Q2)**  \n'
                       "   Used Contextron's textual answers verbatim "
                       '(scale=`""`), as they integrate table data with text '
                       'context about EU grants and Singapore costs.\n'
                       '\n'
                       '2. **Numerical answers (Q3-Q6)**  \n'
                       "   - Values extracted directly from Contextron's "
                       'numerical outputs  \n'
                       '   - Scales unified to `"million"` per evidence ($55M '
                       '→ 55 + million)  \n'
                       '   - Arithmetic results preserved (average=83/6.3, '
                       'change=67)  \n'
                       '   - Format adheres to TATQA standards (strings '
                       'without symbols).\n'
                       '\n'
                       '3. **Consistency checks**  \n'
                       '   All answers align between TabuSynth (table data) '
                       'and Contextron (table+text), with no missing '
                       'information detected. Visura provided no conflicting '
                       'image analysis.'}}
